Measurement of circulating CD21-CD27- B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers.
Fiche du document
2 juin 2022
- doi: 10.1038/s41598-022-12775-4
- issn: 2045-2322
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41598-022-12775-4
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35654865
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2045-2322
Ce document est lié à :
info:eu-repo/grantAgreement/SNF/Careers/PZ00P3_173950///
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_79225BAA39D63
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
B lymphocytes Bursa equivalent cells Bone marrow derived cellsCiter ce document
A. Horisberger et al., « Measurement of circulating CD21-CD27- B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers. », Serveur académique Lausannois, ID : 10.1038/s41598-022-12775-4
Métriques
Partage / Export
Résumé
Determining disease activity in systemic lupus erythematosus (SLE) patients is challenging and limited by the lack of reliable biomarkers. Abnormally activated B cells play a key role in the pathogenesis of SLE, but their measure in clinical practice is currently not recommended. Here, we studied peripheral B cells to identify a valid biomarker. We analyzed peripheral B cells in a discovery cohort of 30 SLE patients compared to 30 healthy controls (HC) using mass cytometry and unsupervised clustering analysis. The relevant B cell populations were subsequently studied by flow cytometry in a validation cohort of 63 SLE patients, 28 autoimmune diseases controls and 39 HC. Our data show an increased frequency of B cell populations with activated phenotype in SLE compared to healthy and autoimmune diseases controls. These cells uniformly lacked the expression of CD21 and CD27. Measurement of CD21 - CD27 - B cells in the blood identified patients with active disease and their frequency correlated with disease severity. Interestingly, we did not observe an increase in the frequency of CD21 - CD27 - B cells in patients with clinically inactive disease but with elevated conventional biomarkers (anti-dsDNA and complement levels). Accordingly, measurement of CD21 - CD27 - B cells represents a robust and easily accessible biomarker to assess the activity of the disease in SLE patients.